Rangnekar VM - Search Results

1

Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.

Munisamy M, Mukherjee N, Thomas L, Pham AT, Shakeri A, Zhao Y, Kolesar J, Rao PPN, Rangnekar VM, Rao M. Munisamy M, et al. Among authors: rangnekar vm. Am J Cancer Res. 2021 Dec 15;11(12):5762-5781. eCollection 2021. Am J Cancer Res. 2021. PMID: 35018225 Free PMC article. Review.

2

The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target.

Goswami A, Ranganathan P, Rangnekar VM. Goswami A, et al. Among authors: rangnekar vm. Cancer Res. 2006 Mar 15;66(6):2889-92. doi: 10.1158/0008-5472.CAN-05-4458. Cancer Res. 2006. PMID: 16540633 Review.

3

Novel mechanism of apoptosis resistance in cancer mediated by extracellular PAR-4.

Burikhanov R, Shrestha-Bhattarai T, Qiu S, Shukla N, Hebbar N, Lele SM, Horbinski C, Rangnekar VM. Burikhanov R, et al. Among authors: rangnekar vm. Cancer Res. 2013 Jan 15;73(2):1011-9. doi: 10.1158/0008-5472.CAN-12-3212. Epub 2012 Nov 30. Cancer Res. 2013. PMID: 23204231 Free PMC article.

4

Value added by an inter-continental cancer consortium.

Rao M, Venkatraman P, Mukhopadhyay D, Roychoudhury S, Vanderford NL, Rangnekar VM. Rao M, et al. Among authors: rangnekar vm. Genes Cancer. 2021 May 21;12:65-68. doi: 10.18632/genesandcancer.215. eCollection 2021. Genes Cancer. 2021. PMID: 34046148 Free PMC article. No abstract available.

5

Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.

Kolesar J, Peh S, Thomas L, Baburaj G, Mukherjee N, Kantamneni R, Lewis S, Pai A, Udupa KS, Kumar An N, Rangnekar VM, Rao M. Kolesar J, et al. Among authors: rangnekar vm. Mol Cancer. 2022 Feb 24;21(1):61. doi: 10.1186/s12943-022-01534-8. Mol Cancer. 2022. PMID: 35209919 Free PMC article. Review.

6

Crizotinib induces Par-4 secretion from normal cells and GRP78 expression on the cancer cell surface for selective tumor growth inhibition.

Burikhanov R, Ganguly S, Ellingson S, Sviripa VM, Araujo N, Li S, Venkatraman P, Rao M, Choughule A, Brainson CF, Zhan CG, Spielmann HP, Watt DS, Govindan R, Rangnekar VM. Burikhanov R, et al. Among authors: rangnekar vm. Am J Cancer Res. 2023 Mar 15;13(3):976-991. eCollection 2023. Am J Cancer Res. 2023. PMID: 37034206 Free PMC article.

7

Increased Gene Expression of C1orf74 Is Associated with Poor Prognosis in Cervical Cancer.

Parida P, Lewis S, Sharan K, Kamal MV, Kumar NAN, Godkhindi VM, Varambally S, Rangnekar VM, Rao M, Damerla RR. Parida P, et al. Among authors: rangnekar vm. Cells. 2023 Oct 27;12(21):2530. doi: 10.3390/cells12212530. Cells. 2023. PMID: 37947608 Free PMC article.

8

Integration of pan-omics technologies and three-dimensional in vitro tumor models: an approach toward drug discovery and precision medicine.

Jose A, Kulkarni P, Thilakan J, Munisamy M, Malhotra AG, Singh J, Kumar A, Rangnekar VM, Arya N, Rao M. Jose A, et al. Among authors: rangnekar vm. Mol Cancer. 2024 Mar 9;23(1):50. doi: 10.1186/s12943-023-01916-6. Mol Cancer. 2024. PMID: 38461268 Free PMC article. Review.

9

Immunoprecipitation of interleukin-1 receptors from a mouse thymoma cell line, EL-4.

Rangnekar VM, Thomas LS, Plate JM. Rangnekar VM, et al. J Biol Chem. 1988 Nov 5;263(31):16408-13. J Biol Chem. 1988. PMID: 2972709 Free article.

10

Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression.

Chakraborty M, Qiu SG, Vasudevan KM, Rangnekar VM. Chakraborty M, et al. Among authors: rangnekar vm. Cancer Res. 2001 Oct 1;61(19):7255-63. Cancer Res. 2001. PMID: 11585763

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

130 results

Search Page